Prescription Drug Monitoring Act of 2019

United States116th CongressHR-3974House of Representatives
Updated: Jul 26, 2019

Summary

Prescription Drug Monitoring Act of 2019 This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours. The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

Latest companion bill action

S-516: Prescription Drug Monitoring Act of 2019

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  1. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  2. Introduced in House

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.